Biphasic concentration change during continuous midazolam administration in brain-injured patients undergoing therapeutic moderate hypothermia

Resuscitation

Volumn 60, Issue 2, 2004, Pages 225-230

  Fukuoka, Noriyasu ^a   Aibiki, Mayuki ^a,b   Tsukamoto, Toyohisa ^a   Seki, Keisuke ^a   Morita, Shushi ^a  

^a KAGAWA UNIVERSITY   (Japan)

^b EHIME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Body temperature; Midazolam; Pharmacokinetics; Therapeutic moderate hypotherrnia

Indexed keywords

ACICLOVIR; BUPRENORPHINE; CYTOCHROME; DOBUTAMINE; MIDAZOLAM; VECURONIUM;

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD LEVEL; BODY TEMPERATURE; BRAIN HEMORRHAGE; BRAIN INJURY; CLINICAL ARTICLE; CLINICAL TRIAL; DISTRIBUTION VOLUME; DRUG CLEARANCE; DRUG ELIMINATION; ENCEPHALITIS; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; INDUCED HYPOTHERMIA; INTENSIVE CARE UNIT; MALE; MODEL; PRIORITY JOURNAL; RANK SUM TEST; STATISTICAL ANALYSIS;

EID: 1242292323     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2003.09.017     Document Type: Article

References (24)

1. Aibiki M., Maekawa S., Ogura S., Kinoshitay Y., Kawai N., Yokono S. Effect of moderate hypothermia on systemic and internal jugular plasma IL-6 levels after traumatic brain injury in humans. J. Neurotrauma. 16:1999;225-232.
2. Aibiki M., Maekawa S., Yokono S. Moderate hypothermia improves imbalances of thromboxane A2 and prostaglandin I2 production after traumatic brain injury in humans. Critic. Care Med. 28:2000;3902-3906.
3. Marion D.W., Penrod L.E., Kelsey S.F., Obrist W.D., Kochanek P.M., Palmer A.M.et al. Treatment of traumaric brain injury with moderate hypothermia. N. Engl. J. Med. 336:1997;540-546.
4. The Hypothermia After Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 21Feb2002;346:549-56.
5. Aibiki M., Maekawa S., Seki K., Nishiyama T., Yokono S. Activated cytokine production in patients with accidental hypothermia. Resuscitation. 41:1999;263-268.
6. Goh B.C., Lee S.C., Wang L.Z., Fan L., Guo J.Y., Lamba J.et al. Explaining interindividual variability of docetaxel pharmacokinetics and pharmacodynamics in Asians through phenotyping and genotyping strategies. J. Clin. Oncol. 20:2002;3683-3690.
7. Metz C., Holzschuh M., Bein T., Woertgen C., Frey A., Frey I.et al. Moderate hypothermia in patients with severe head injury cerebral and extracerebral effects. J. Neurosurg. 85:1996;533-541.
8. Aibiki M, Kawaguchi S, Umegaki O, Ogura S, Kawai N, Kinoshita Y, Yokono S. Intravascular volume expansion during therapeutic moderate hypothermia for brain-injured patients: preliminary report. In: Hayashi N, editors. Brain Hypothermia. Tokyo: Springer; 2000. p. 161-8.
9. Saitoh T., Kokue E., Shimoda M. The suppressive effects of lipopolysaccharide-induced acute phase response on hepatic cytochrome P450-dependent drug metabolism in rabbits. J. Vet. Pharmacol. Ther. 22:1999;87-95.
10. ter Horst P.G., Foudraine N.A., Cuypers G., Oldenhof N.J. Simultaneous determination of levomepromazine, midazolam and their major metabolites in human plasma by reversed-phase liquid chromatography. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 791:2003;389-398.
11. Yamaoka K., Tanigawara Y., Nakagawa T., Uno T. A pharmacokinetic analysis program (multi) for microcomputer. J. Pharmacobiodyn. 4:1981;879-885.
12. Zomorodi K., Donner A., Somma J., Barr J., Sladen R., Ramsay J.et al. Population pharmacokinetics of midazolam administered by target controlled infusion for sedation following coronary artery bypass grafting. Anesthesiology. 89:1998;1418-1429.
13. Barr J., Zomorodi K., Bertaccini E.J., Shafer S.L., Geller E. A double-blind, randomized comparison of i.v. lorazepam versus midazolam for sedation of ICU patients via a pharmacologic model. Anesthesiology. 95:2001;286-298.
14. Rekka E., Evdokimova E., Eeckhoudt S., Labar G., Calderon P.B. Role of temperature on protein and mRNA cytochrome P450 3A (CYP3A) isozymes expression and midazolam oxidation by cultured rat precision-cut liver slices. Biochem. Pharmacol. 64:2002;633-643.
15. Ibrahim A., Karim A., Feldman J., Kharach E. The influence of parecoxib, a parenteral cyclooxygenase-2 specific inhibitor, on the pharmacokinetics and clinical effects of midazolam. Anesth. Anaig. 95:2002;667-673.
16. Xu H., Aibiki M., Seki K., Ogura S., Yokono S., Ogli K., Effects of induced hypothermia on renal sympathetic nerve activity and baroreceptor reflex in urethane-anesthetized rabbits Critic. Care Med. 28:2000;3854-3860.
17. Kinoshita K., Sakurai A., Mera K., Shirai K., Hone J., Moriya T.et al. Midazolam for continuous sedation in Japanese critical care patients phase II study. J. Int. Med. Res. 29:2001;342-348.
18. Pea F., Furlanut M., Pharmacokinetic aspects of treating infections in the intensive care unit: focus on drug interactions Clin. Pharmacokinet. 40:2001;833-868.
19. Fry D.E. The importance of antibiotic pharmacokinetics in critical illness. Am. J. Surg. 172:1996;205-255.
20. Benet LZ, Kroetz DL, Sheiner LB. Pharmacokinetics. In: Hardinan et al., editors. Good and Gilman's the pharmacological basis of therapeutics, 9th ed. New York: McGraw-Hill; 1990. p. 3-28.
21. Albrecht S., Ihmsen H., Hering W., Geisslinger G., Dingemanse J., Schwilden H.et al. The effect of age on the pharmacokinetics and pharmacodynamics of midazolam. J. Clin. Pharmacol. Ther. 65:1999;630-639.
22. Rocca P., Bellone G., Benna P., Bergamasco B., Ravizza L., Ferrero P. Peripheral-type benzodiazepine receptors and diazepam binding inhibitor-like immunoreactivity distribution in human peripheral blood mononuclear cells. Immunopharmacology. 25:1993;163-178.
23. Heller A., Heller S., Blecken S., Urbaschek R., Koch T. Effects of intravenous anesthetics on bacterial elimination in human blood in vitro. Acta Anaesthesiol. Scand. 42:1998;518-526.
24. Aibiki M., Kawaguchi S., Maekawa N. Reversible hypophosphatemia during moderate hypothermia therapy for brain-injured patients. Critic. Care Med. 29:2001;1726-1730.